Novick AC - Search Results

1

Innovations and challenges in renal cancer: consensus statement from the first international conference.

Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Atkins MB, et al. Among authors: novick ac. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. doi: 10.1158/1078-0432.CCR-040720. Clin Cancer Res. 2004. PMID: 15448017 Review. No abstract available.

2

Clinical practice guidelines: renal cell carcinoma.

Bukowski RM, Novick AC. Bukowski RM, et al. Among authors: novick ac. Cleve Clin J Med. 1997;64 Suppl 1:SI1-44; quiz SI45-7. doi: 10.3949/ccjm.64.s1.4. Cleve Clin J Med. 1997. PMID: 9239949 Free article. Review.

3

Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.

Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, Olencki T, Budd GT, McLain D, Elson P, Novick A, Finke JH. Bukowski RM, et al. Clin Cancer Res. 1998 Oct;4(10):2337-47. Clin Cancer Res. 1998. PMID: 9796963 Clinical Trial.

4

Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.

Bukowski RM, Rayman P, Molto L, Tannenbaum CS, Olencki T, Peereboom D, Tubbs R, McLain D, Budd GT, Griffin T, Novick A, Hamilton TA, Finke J. Bukowski RM, et al. Clin Cancer Res. 1999 Oct;5(10):2780-9. Clin Cancer Res. 1999. PMID: 10537342

5

Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.

Olencki T, Peereboom D, Wood L, Budd GT, Novick A, Finke J, McLain D, Elson P, Bukowski RM. Olencki T, et al. J Cancer Res Clin Oncol. 2001 May;127(5):319-24. doi: 10.1007/s004320000211. J Cancer Res Clin Oncol. 2001. PMID: 11355147 Clinical Trial.

6

Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma.

Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, Finke JH. Kolenko V, et al. Among authors: novick ac. Cancer Res. 1999 Jun 15;59(12):2838-42. Cancer Res. 1999. PMID: 10383143

7

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Figlin RA, et al. Among authors: novick ac. J Clin Oncol. 1999 Aug;17(8):2521-9. doi: 10.1200/JCO.1999.17.8.2521. J Clin Oncol. 1999. PMID: 10561318 Clinical Trial.

8

Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.

Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, Finke JH. Ng CS, et al. Among authors: novick ac. Urology. 2002 Jan;59(1):9-14. doi: 10.1016/s0090-4295(01)01503-5. Urology. 2002. PMID: 11796271 Review. No abstract available.

9

Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.

Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH. Uzzo RG, et al. Among authors: novick ac. Clin Cancer Res. 1999 May;5(5):1219-29. Clin Cancer Res. 1999. PMID: 10353760

10

GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction.

Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, Das T, Zhang R, Chahlavi A, Tannenbaum CS, Novick A, Bukowski R, Finke JH. Biswas K, et al. Cancer Res. 2006 Jul 1;66(13):6816-25. doi: 10.1158/0008-5472.CAN-06-0250. Cancer Res. 2006. PMID: 16818659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

544 results

Search Page